Literature DB >> 2357771

Cardiovascular autonomic function in anthracycline-treated breast cancer patients.

M Viniegra1, M Marchetti, M Losso, A Navigante, S Litovska, A Senderowicz, L Borghi, J Lebron, D Pujato, H Marrero.   

Abstract

Preclinical studies suggest that in addition to the well-known direct damage to the myocardium, anthracycline antineoplastic drugs exert toxic effects on the cardiovascular autonomic system as well. To investigate whether this phenomenon occurs in the clinic, we carried out noninvasive, widely used tests of cardiovascular autonomic physiology in 55 women with stage II or III breast cancer. In all, 31 were being treated with anthracycline-containing chemotherapy regimens, and 24 who were receiving CMF (cyclophosphamide, Methotrexate, and fluorouracil) served as controls. Of 279 tests conducted in anthracycline (A)-treated patients, 123 were abnormal, vs 54 of 216 tests carried out in 24 controls (44% vs 25%; P less than 0.005). Abnormal variations in heart rate on standing and in diastolic blood pressure during handgrip was found in 25 (81%) and 17 patients receiving A, vs 9 (37%; P less than 0.005) and 5 (21%; P less than 0.0001), respectively, in controls. The incidence of abnormal tests was significantly higher in A-treated patients greater than 60 years of age (41%) vs 67%; P less than 0.05). Radionuclide ventriculography was carried out in 19 patients who showed abnormal tests of cardiovascular autonomic function after greater than or equal to 6 courses of a-containing chemotherapy; only 1 of them had abnormal cardiac contractility (global hypokinesia), suggesting that abnormal tests of cardiovascular autonomic function may occur in the absence of a detectable deterioration in left ventricular ejection fraction. A large number of factors may alter cardiovascular autonomic function in cancer patients, including age, radiation therapy to the chest, and multidrug treatment. Even after correcting for the most obvious of these, chemotherapy with anthracyclines is associated with a significantly higher percentage of abnormal tests for cardiovascular autonomic function. Although indirect and semi-quantitative, our results are compatible with the idea of A-induced cardiac autonomic dysfunction.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2357771     DOI: 10.1007/bf02897205

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  41 in total

Review 1.  The Valsalva maneuver and response revisited.

Authors:  R A Nishimura; A J Tajik
Journal:  Mayo Clin Proc       Date:  1986-03       Impact factor: 7.616

2.  Cardiorespiratory arrest and diabetic autonomic neuropathy.

Authors:  M M Page; P J Watkins
Journal:  Lancet       Date:  1978-01-07       Impact factor: 79.321

3.  Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications.

Authors:  D J Ewing; I W Campbell; B F Clarke
Journal:  Ann Intern Med       Date:  1980-02       Impact factor: 25.391

4.  Experimental animal models of adriamycin cardiotoxicity.

Authors:  J H Doroshow; G Y Locker; C E Myers
Journal:  Cancer Treat Rep       Date:  1979-05

5.  Vinca alkaloid-induced cardiovascular autonomic neuropathy.

Authors:  E Roca; E Bruera; P M Politi; M Barugel; L Cedaro; S Carraro; R D Chacón
Journal:  Cancer Treat Rep       Date:  1985-02

6.  Aclarubicin-associated QTc prolongation and ventricular fibrillation.

Authors:  N Iwata; M Karasawa; M Omine; T Maekawa; T Suzuki; Y Kawai
Journal:  Cancer Treat Rep       Date:  1984-03

7.  Differential changes of autonomic nervous system function with age in man.

Authors:  M A Pfeifer; C R Weinberg; D Cook; J D Best; A Reenan; J B Halter
Journal:  Am J Med       Date:  1983-08       Impact factor: 4.965

8.  Doxorubicin: a fluorescent neurotoxin retrogradely transported in the central nervous system.

Authors:  L Y Koda; D Van der Kooy
Journal:  Neurosci Lett       Date:  1983-03-28       Impact factor: 3.046

9.  Effects of doxorubicin on the release of catecholamines from the bovine adrenal medulla.

Authors:  J E Pinto; P M Politi; B Fernandez
Journal:  Arch Int Pharmacodyn Ther       Date:  1987-09

10.  Heart rate changes in diabetes mellitus.

Authors:  D J Ewing; I W Campbell; B F Clarke
Journal:  Lancet       Date:  1981-01-24       Impact factor: 79.321

View more
  7 in total

1.  Health-related physical fitness assessment in a community-based cancer rehabilitation setting.

Authors:  Amy A Kirkham; Sarah E Neil-Sztramko; Joanne Morgan; Sara Hodson; Sarah Weller; Tasha McRae; Kristin L Campbell
Journal:  Support Care Cancer       Date:  2015-01-25       Impact factor: 3.603

2.  Cardiac autonomic functioning is impaired among allogeneic hematopoietic stem cell transplantation survivors: a controlled study.

Authors:  G Deuring; A Kiss; J P Halter; J R Passweg; P Grossman
Journal:  Bone Marrow Transplant       Date:  2016-07-04       Impact factor: 5.483

Review 3.  Anthracyclines and the heart.

Authors:  W Rhoden; P Hasleton; N Brooks
Journal:  Br Heart J       Date:  1993-12

4.  Doxorubicin treatments induce significant changes on the cardiac autonomic nervous system in childhood acute lymphoblastic leukemia long-term survivors.

Authors:  Maxime Caru; Denis Corbin; Delphine Périé; Valérie Lemay; Jacques Delfrate; Simon Drouin; Laurence Bertout; Maja Krajinovic; Caroline Laverdière; Gregor Andelfinger; Daniel Sinnett; Daniel Curnier
Journal:  Clin Res Cardiol       Date:  2019-02-18       Impact factor: 5.460

Review 5.  Cardiovascular Autonomic Dysfunction in Patients with Cancer.

Authors:  Ben G T Coumbe; John D Groarke
Journal:  Curr Cardiol Rep       Date:  2018-07-03       Impact factor: 2.931

6.  Impact of cancer and chemotherapy on autonomic nervous system function and cardiovascular reactivity in young adults with cancer: a case-controlled feasibility study.

Authors:  Scott C Adams; Ronald Schondorf; Julie Benoit; Robert D Kilgour
Journal:  BMC Cancer       Date:  2015-05-18       Impact factor: 4.430

7.  Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes.

Authors:  Fangyi Sun; Jing Shi; Cuizhi Geng
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.